Pulmonary Medication Adherence and Health-care Use in Cystic Fibrosis
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Background Poor treatment adherence is common in cystic fibrosis (CF) and may lead to worse health outcomes and greater health-care use. This study evaluated associations of adherence to pulmonary medications, age, health-care use, and cost among patients with CF. Methods Patients with CF aged ≥ 6 years were identified in a national commercial claims database. A 12-month medication possession ratio (MPR) was computed for each pulmonary medication and then averaged for a composite MPR (CMPR) for each patient. The CMPR was categorized as low ( Results Mean CMPR for the sample (N = 3,287) was 48% ± 31%. Age was inversely related to CMPR. In the concurrent year, more CF-related hospitalizations were observed among patients with low (event rate ratio [ERR], 1.35; 95% CI, 1.15-1.57) and moderate (ERR, 1.25; 95% CI, 1.05-1.48) vs high adherence; similar associations were observed for all-cause hospitalizations and CF-related and all-cause acute care use (hospitalizations + ED) in the concurrent and subsequent year. Rates of CF-related and all-cause outpatient visits did not differ by adherence. Low and moderate adherence predicted higher concurrent health-care costs by $14,211 ($5,557-$24,371) and $8,493 (-$1,691 to $19,709), respectively, compared with high adherence. Conclusions Worse adherence to pulmonary medications was associated with higher acute health-care use in a national, privately insured cohort of patients with CF. Addressing adherence may reduce avoidable health-care…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Low adherence to all treatments is associated with an increased number of pulmonary exacerbations requiring intravenous (IV) antibiotics (Eakin 2011) and hospitalisations, which incur higher healthcare costs (Quittner 2014).”
From Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis (2023) · cites this paper as Quittner 2014
Citations
Cites
Physician Communication and Patient Adherence to Treatment: A Meta-Analysis
Haskard Zolnierek, K. B., & DiMatteo, M. R. (2009) · Medical Care · doi:10.1097/mlr.0b013e31819a5acc · Cited by 2,489
Patient Adherence and Medical Treatment Outcomes: A Meta-Analysis
Robin DiMatteo, M., Giordani, P. J., Lepper, H. S., & Croghan, T. W. (2002) · Medical Care · doi:10.1097/00005650-200209000-00009 · Cited by 1,490
Interventions to Enhance Patient Adherence to Medication Prescriptions: Scientific Review
McDonald, H. P., Garg, A. X., & Haynes, R. B. (2002) · JAMA · doi:10.1001/jama.288.22.2868 · Cited by 1,176
Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health
Flume, P. A., O'Sullivan, B. P., Robinson, K. A., Goss, C. H., Mogayzel, P. J., Willey-Courand, D. B., Bujan, J., Finder, J., Lester, M., Quittell, L., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200705-664oc · Cited by 1,024
A Controlled Trial of Long-Term Inhaled Hypertonic Saline in Patients with Cystic Fibrosis
Elkins, M. R., Robinson, M., Rose, B. R., Harbour, C., Moriarty, C. P., Marks, G. B., Belousova, E. G., Xuan, W., & Bye, P. T. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa043900 · Cited by 862
Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health
Mogayzel, P. J., Naureckas, E. T., Robinson, K. A., Mueller, G., Hadjiliadis, D., Hoag, J. B., Lubsch, L., Hazle, L., Sabadosa, K., Marshall, B., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201207-1160oe · Cited by 615
Kahana, S., Drotar, D., & Frazier, T. (2008) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/jsm128 · Cited by 334
How patient cost-sharing trends affect adherence and outcomes: a literature review.
Eaddy, M. T., Cook, C. L., O'Day, K., Burch, S. P., & Cantrell, C. R. (2012) · Europe PMC (PubMed Central) · Cited by 329
Barriers to Treatment Adherence for Children with Cystic Fibrosis and Asthma: What Gets in the Way?
Modi, A. C., & Quittner, A. L. (2006) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/jsj096 · Cited by 301
Self-citationA multi-method assessment of treatment adherence for children with cystic fibrosis
Modi, A. C., Lim, C. S., Yu, N., Geller, D., Wagner, M. H., & Quittner, A. L. (2006) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2006.03.002 · Cited by 265
Self-citation
Research works printed but not linked: 2
- Pressler, 2011, Aztreonam for inhalation solution, an aerosolized antibiotic for the treatment of pseudomonal airway infection in patients with cystic fibrosis, US Res Dis, 7, 107
- Quinn, 2004, Measuring, predicting and improving adherence to inhalation in patients with CF: a randomised controlled study of motivational interviewing [abstract], Pediatr Pulmonol, 38, 360
Cited by
Items 101–200 of 251
Girón, R. M., Peláez, A., Ibáñez, A., Martínez-Besteiro, E., Gómez-Punter, R. M., Martínez-Vergara, A., Ancochea, J., & Morell, A. (2022) · Antibiotics · doi:10.3390/antibiotics11111637 · Cited by 12
Green, N., Manwani, D. G., Aygün, B., Appiah‐Kubi, A., Smith‐Whitley, K., Castillo, Y., Soriano, L., Jia, H., & Smaldone, A. M. (2024) · Pediatric Blood & Cancer · doi:10.1002/pbc.30878 · Cited by 13
Gardner, A. J., Gray, A., Self, S. T., & Wagener, J. S. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s130439 · Cited by 12
Basile, M. J., Andrews, J., Wang, J., Hadjiliadis, D., Henthorne, K., Fields, S. A., Kozikowski, A., Huamantla, J., & Hajizadeh, N. (2019) · Patient Education and Counseling · doi:10.1016/j.pec.2019.06.007 · Cited by 13
Morton, R., Elphick, H., Edwards, E., Daw, W., & West, N. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s123723 · Cited by 13
“This increased morbidity has been shown to increase health care utilization and associated cost.(3) Adherence to nebulized medication is difficult to accurately measure, as subjective measures such as asking the patient and self-filled questionnaires have been shown to overestimate rates due to the social desirability…”
BackgroundHorky, S. C., Sherman, L., Polvinen, J., Saxena, M., & Rich, M. (2017) · Patient Experience Journal · doi:10.35680/2372-0247.1200 · Cited by 14
“However, these treatments are burdensome and time-consuming,(2,3) contributing to decreased quality of life(4) and poor adherence.(5) Understanding an adolescent’s internal experience, including the components of his or her identity, can support a stronger, more trusting patientprovider relationship, leading to increa…”
BackgroundAdherence to Nutritional Supplementation in Cystic Fibrosis
Hommel, K. A., Rausch, J. R., Towner, E., Schall, J. I., Maqbool, A., Mascarenhas, M. R., & Stallings, V. A. (2019) · Journal of Pediatric Nursing · doi:10.1016/j.pedn.2019.04.011 · Cited by 17
Adherence and barriers to general and respiratory exercises in cystic fibrosis
Santuzzi, C. H., Liberato, F. M. G., Morau, S. A. C., Ferreira, N. D. O., & Nascimento, L. R. (2020) · Pediatric Pulmonology · doi:10.1002/ppul.24912 · Cited by 14
“Multiple therapies with an exhaustive treatment routine, in addition to the lack of curative treatment,(13) may be an aggravating factor to non‐adherence to exercises in CF, which is associated with increased risk of hospitalization, longer hospital stays, and pulmonary exacerbations.(14,15) Previous studies(16,17) ha…”
BackgroundWildman, M. J., O’Cathain, A., Hind, D., Maguire, C., Arden, M. A., Hutchings, M., Bradley, J. M., Walters, S. J., Whelan, P., Ainsworth, J. D., et al. (2021) · Programme Grants for Applied Research · doi:10.3310/pgfar09110 · Cited by 14
An empirical method to cluster objective nebulizer adherence data among adults with cystic fibrosis
Hoo, Z. H., Campbell, M. J., Curley, R., & Wildman, M. J. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s131497 · Cited by 12
“However, a 5-fold increase in adherence from 20% to 100% is very likely to have clinical benefits by reducing the frequency of pulmonary exacerbations and decreasing healthcare costs.(9,22) Given the likely threshold effect of nebulizer adherence, clustering adherence data makes sense when we are analyzing data, to be…”
BackgroundInfluentialHamed, K. A., Conti, V., Tian, H., & Loefroth, E. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s134759 · Cited by 12
“12,13 Tobramycin inhalation powder (TIP; TOBI ® Podhaler™, Novartis Pharma AG, Basel, Switzerland) is the first dry-powder inhaled antibiotic available for use in CF patients; it uses PulmoSphere ® technology for efficient drug delivery into the lower airways.”
Santoleri, F., Auriemma, L., Spacone, A., Marinari, S., Esposito, F., Vita, F. D., Petragnani, G., Fabio, C. D., Fabio, L. D., & Costantini, A. (2021) · Journal of Pharmacy Practice · doi:10.1177/08971900211008625 · Cited by 14
“Data at our disposal show that adherence to treatment in patients with pulmonary diseases is low.(40) Though efficacy is influenced by treatment adherence, only a few studies have heretofore been conducted on IPF.”
BackgroundPharmacists’ perspectives on monitoring adherence to treatment in Cystic Fibrosis
Mooney, K. M., Ryan, C. A., & Downey, D. G. (2015) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-015-0239-4 · Cited by 10
Caverly, L. J., Caverly, T. J., Kalikin, L. M., Foster, B. K., Simon, R. H., & LiPuma, J. J. (2016) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2016.04.009 · Cited by 10
“, tobramycin) antibiotics are well described in individuals with CF [11,12].”
BackgroundAbraham, O., LeMay, S., Nixon, G., Braun, A. T., Decker, C. A., & Szela, L. (2021) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2021.04.006 · Cited by 10
Use of inhaled antibiotics among Danish patients with cystic fibrosis
Møller, R., Nielsen, B. U., Faurholt‐Jepsen, D., Katzenstein, T. L., Skov, M., Philipsen, L. K. D., Pressler, T., Johansen, H. K., & Qvist, T. (2022) · Pediatric Pulmonology · doi:10.1002/ppul.25942 · Cited by 9
Changing Epidemiology of Pediatric Pulmonary Exacerbations in Cystic Fibrosis
Fireizen, Y., Ahmed, M., Vigers, T., Akong, K., Ryu, J., Hahn, A., Fanous, H., Koumbourlis, A. C., Tirakitsoontorn, P., Arrieta, A. C., et al. (2025) · Pediatric Pulmonology · doi:10.1002/ppul.71019 · Cited by 11
Me, myself, and I: A systematic review of cystic fibrosis and self‐concept
Harrigan, M., Jessup, M., Bennett, K., & Mulrennan, S. A. (2024) · Pediatric Pulmonology · doi:10.1002/ppul.26916 · Cited by 19
“48 This is particularly pertinent for young people with CF, who must reconcile where chronic disease sits within their identity and develop autonomy in managing a complex treatment regime.”
BackgroundHoo, Z. H., Wildman, M. J., Curley, R., Walters, S. J., & Campbell, M. J. (2017) · Respirology · doi:10.1111/resp.13174 · Cited by 10
Mental health history and social barriers impacting caregivers of infants with cystic fibrosis
Gillespie, M. L., Nemastil, C. J., Moore‐Clingenpeel, M., Gilmore, D., Dell, M. L., & Krivchenia, K. (2020) · Pediatric Pulmonology · doi:10.1002/ppul.25213 · Cited by 10
“Poor adherence negatively impacts patient outcomes, resulting in increased pulmonary exacerbations, decline in lung function, increased hospitalizations, and increased healthcare costs.(5) Factors found to correlate with poor adherence include poor knowledge of disease management, low self‐esteem, poor mental health,…”
Backgrounddel Corral, T., Touche, R. L., Iranzo, M. À. C. I., Olmos, R., Blanco-Royano, F., & López‐de‐Uralde‐Villanueva, I. (2020) · Physical Therapy · doi:10.1093/ptj/pzaa136 · Cited by 10
Bevan, A., Hoo, Z. H., Totton, N., Girling, C., Davids, I. R., Whelan, P., Antrobus, S., Ainsworth, J. D., Buchan, I. E., Anderson, A. J. B., et al. (2021) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2021.09.007 · Cited by 9
Sawicki, G. S., Goodman, A. S., Bacon, C., Collins, L., Greenberg, J., Duncan, C. L., Frederick, C., Luebbert, S., Mazuera, S., Polineni, D., et al. (2023) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2023.04.015 · Cited by 9
Self-citationPatient Knowledge and Clinic Attendance in Adolescent Patients with Cystic Fibrosis
Kazmerski, T. M., Miller, E. P., Abebe, K. Z., Matisko, J., Schachner, D., & Spahr, J. E. (2015) · Pediatric Allergy Immunology and Pulmonology · doi:10.1089/ped.2014.0475 · Cited by 9
“25 In light of the rising number of adolescents and adults with CF, finding novel ways to optimize this habilitation is a priority.”
Gramegna, A., Misuraca, S., Lombardi, A., Premuda, C., Barone, I., Ori, M., Amati, F., Retucci, M., Nazzari, E., Alicandro, G., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02612-1 · Cited by 8
“Suboptimal adherence can negatively impact health outcomes such as the rate of pulmonary exacerbations, quality of life, and health care costs [94– 97].”
BackgroundHatziagorou, E., Manika, Κ., Kyrvasili, S., Kotoulas, S., Chrysochoou, E., Kouroukli, E., Sionidou, M., & Tsanakas, J. N. (2022) · Pediatric Pulmonology · doi:10.1002/ppul.26126 · Cited by 9
“Finally, Quittner et al.(6) showed that low adherence increases the need for hospitalization and healthcare cost.”
BackgroundInfluentialAdherence to medicine in adolescence
Pearce, C. J., Azam, A., Barry, P. J., & d’Ancona, G. (2024) · European Respiratory Society eBooks · doi:10.1183/2312508x.10011223 · Cited by 7
Evaluating Long-Term Benefits of Chronic Azithromycin. Furthering Our Quest for Precision Medicine
Saiman, L. M., & Schechter, M. S. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201911-2234ed · Cited by 7
“Furthermore, in the real world, adherence to chronic CF therapies is about 50% (16).”
BackgroundThe dance of cystic fibrosis: Experiences of living with cystic fibrosis as an adult
Varilek, B. M., & Isaacson, M. J. (2020) · Journal of Clinical Nursing · doi:10.1111/jocn.15397 · Cited by 8
Lumley, E., Drabble, S. J., Scott, A., Wildman, M. J., & O’Cathain, A. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s353434 · Cited by 9
Survey of collaborative mental health providers in cystic fibrosis centers in the United States
García, G., Oliva, M., & Smith, B. A. (2015) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2015.03.005 · Cited by 7
O'Toole, D., Latchford, G. J., Duff, A. J. A., Ball, R., McCormack, P., McNamara, P. S., Brownlee, K. G., & Southern, K. W. (2018) · Qualitative Health Research · doi:10.1177/1049732318805754 · Cited by 11
Clinical outcomes of digital health in adults with cystic fibrosis
Carnovale, V., Iacotucci, P., Qiao, D., Ferrillo, L., Somma, J., Buonaurio, S., D’Ippolito, M., Celardo, A., & Savi, D. (2022) · Respiratory Medicine · doi:10.1016/j.rmed.2022.106970 · Cited by 5
Assessment of long‐term medication adherence with cystic fibrosis: An integrated approach
Platt, T. L., Kormelink, L. N., Autry, E. B., Rossoll, S. J., & Kuhn, R. J. (2023) · Pediatric Pulmonology · doi:10.1002/ppul.26774 · Cited by 6
TREATMENT ADHERENCE AMONG CHILDREN AND ADOLESCENTS IN A CYSTIC FIBROSIS REFERENCE CENTER
Bonfim, B. S., Filho, V. M. D. M., Fontenelle, F. M., & Souza, E. L. (2020) · Revista Paulista de Pediatria · doi:10.1590/1984-0462/2020/38/2018338 · Cited by 12
Randomised controlled trial of nebulised gentamicin in children with bronchiectasis
Twiss, J., Stewart, A. W., Gilchrist, C. A., Keelan, J. A., Metcalfe, R., & Byrnes, C. A. (2022) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.15899 · Cited by 8
Oubaya, N., Pombet, T., Delestrain, C., Remus, N., Douvry, B., Grenet, D., Corvol, H., Thouvenin, G., Prulière-Escabasse, V., Mounir, H., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.978627 · Cited by 9
Patient Perspectives on the Use of Digital Technology to Help Manage Cystic Fibrosis
Watanabe, A. H., Willis, C., Ragsdale, R., BISKUPIAK, J. E., Moore, K., Brixner, D. I., & Young, D. C. (2023) · Pulmonary Medicine · doi:10.1155/2023/5082499 · Cited by 6
“People living with CF (PWCF) take an average of 10 medications (±5) per day [6].”
BackgroundPerez, A., Vogt, H., & Pettit, R. S. (2023) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-28.8.741 · Cited by 9
A weekend/weekday comparison of adherence to daily treatment regimens in adults with cystic fibrosis
Keyte, R., Egan, H. H., Jackson, C. A., Nash, E. F., Regan, A., & Mantzios, M. (2017) · Health Psychology Report · doi:10.5114/hpr.2018.72331 · Cited by 5
Bernstein, R. M., Riekert, K. A., & Quittner, A. L. (2018) · Pediatric Allergy Immunology and Pulmonology · doi:10.1089/ped.2017.0850 · Cited by 6
Self-citationSandler, R. D., & Wildman, M. J. (2022) · Healthcare · doi:10.3390/healthcare11010020 · Cited by 10
Cohen‐Cymberknoh, M., Dimand, I., Tanny, T., Blau, H., Mussaffi, H., Kadosh, D., Gärtner, S., Bentur, L., Nir, V., Gur, M., et al. (2023) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2023.04.004 · Cited by 6
Robinson, L., Maguire, C., Hoo, Z. H., & Wildman, M. J. (2020) · F1000Research · doi:10.12688/f1000research.21033.2 · Cited by 6
Butcher, J. L., Siracusa, C. M., Grabowski, H., Yablon, D., Ertman, B., McWilliams, E., Woo, T., Everhart, R. S., Maggs, J., Prickett, M. H., et al. (2025) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2025.07.014 · Cited by 5
Self-citationDiFiglia, S., Dhingra, L. K., Georgiopoulos, A. M., Papia, K., Sullivan, E., Plachta, A., Boccio, C., Portenoy, R. K., & Basile, M. J. (2023) · Life · doi:10.3390/life13081620 · Cited by 9
“Quittner and colleagues [34] found that 4102 caregivers of young children with CF often showed similar or higher levels of depressive symptomatology than adolescents and adults with CF.”
BackgroundMethodRiekert, K. A., Ford, C., Goodman, A. S., Eckmann, T., Green, A., & Quittner, A. L. (2024) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2024.10.011 · Cited by 6
Self-citationPlant, B. J., Downey, D. G., Eustace, J., Gunaratnam, C., HAWORTH, C. S., Jones, A. M., McKone, E. F., Peckham, D. G., Ketchell, R. I., & Bilton, D. (2017) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.02.006 · Cited by 5
“Adherence to treatment is a critical aspect of CF care [10] but the tool and study were not designed to address this.”
BackgroundMethodValidation of a Cystic Fibrosis Medication Knowledge Questionnaire
FitzPatrick, B., Hawboldt, J., Smith, M. J., & Lee, T. A. (2017) · Global Pediatric Health · doi:10.1177/2333794x17719803 · Cited by 6
The Changing Face of Cystic Fibrosis
Cogen, J. D., & Ramsey, B. W. (2020) · Respiratory medicine · doi:10.1007/978-3-030-42382-7_1 · Cited by 5
Girling, C., Packham, A., Robinson, L., Arden, M. A., Hind, D., & Wildman, M. J. (2022) · Implementation Science Communications · doi:10.1186/s43058-022-00263-9 · Cited by 7
Transforming Care Models in Cystic Fibrosis: A Review
Diener, B. L., Berdella, M. N., DeCelie-Germana, J., Stables-Carney, T., & Kier, C. (2025) · Healthcare · doi:10.3390/healthcare13233022 · Cited by 4
“Poor medication adherence has been linked to increased CF-related hospitalizations and higher healthcare costs [24].”
Reamer, C. B., O'Malley, C. A., Nufer, J., & Savant, A. P. (2020) · BMJ Open Quality · doi:10.1136/bmjoq-2019-000890 · Cited by 5
Dawson, S., Rodham, K., Taylor, J. H., Dewar, J. C., & Wildman, M. J. (2023) · Psychology and Health · doi:10.1080/08870446.2023.2254318 · Cited by 7
“In addition to the costs for individuals, low adherence has widespread implications for healthcare services, with higher adherence to CF treatments associated with improved outcomes including reduced hospital admissions (e.g. Quittner et al., 2014) and length of inpatient stays (Nasr et al., 2013).”
Tang, K. W. K., Millar, B. C., & Moore, J. E. (2023) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlad129 · Cited by 5
Martin, R., Arden, M. A., Porritt, J. M., Wildman, M. J., & Naughton, F. (2020) · Healthcare · doi:10.3390/healthcare8010022 · Cited by 5
“Recent work in the UK has demonstrated that patients do engage well with such apparatus [18].”
BackgroundA medication adherence–enhancing simulation intervention in pediatric cystic fibrosis
Schandevyl, G. V., Casimir, G. J., & Hanssens, L. S. (2021) · Journal of Child Health Care · doi:10.1177/13674935211013924 · Cited by 4
“In a study by Quittner et al. (2014), adherence to chronic respiratory medications was measured based on pharmacy refill histories for 3287 CF patients, including both children (≥6 years) and adults.”
BackgroundInfluentialTotton, N., Bradburn, M. J., Hoo, Z. H., Lewis, J., Hind, D., Girling, C., Shepherd, E., Nightingale, J. A., Daniels, T. W. V., Dewar, J. C., et al. (2021) · Health Science Reports · doi:10.1002/hsr2.381 · Cited by 3
Adherence to inhaled therapies over 4 years in people with cystic fibrosis
Manika, Κ., Hatziagorou, E., Kotoulas, S., Kyrvasili, S., Sourla, E., Kouroukli, E., Sionidou, M., Papadaki, E., & Tsanakas, J. N. (2022) · Pediatric Pulmonology · doi:10.1002/ppul.25834 · Cited by 4
“On the other hand, the association between adherence and exacerbations is rather well established.(9,12,13) Interestingly, in the present study, participants with stable adherence had lower pulmonary function parameters both at the beginning of the study period and as a mean compared with those with variable adherence.”
BackgroundResultInfluentialViprey, M., Mougeot, F., Dima, A. L., Haesebaert, J., Occelli, P., Durieu, I., Rouzé, H., Reynaud, Q., & Touzet, S. (2023) · Patient Preference and Adherence · doi:10.2147/ppa.s389792 · Cited by 5
Gilchrist, F. J., Bui, S., Gärtner, S., McColley, S. A., Tiddens, H. A. W. M., Ruiz, G., Stehling, F., Al-ani, M., Gurtovaya, O., Bresnik, M., et al. (2023) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2023.06.008 · Cited by 6
S3-Leitlinie: Lungenerkrankung bei Mukoviszidose – Pseudomonas aeruginosa
Schwarz, C., Bend, J., Hebestreit, H. U., Hogardt, M., Hügel, C., Illing, S., Mainz, J. G., Rietschel, E., Schmidt, S., Schulte-Hubbert, B., et al. (2024) · Pneumologie · doi:10.1055/a-2182-1907 · Cited by 5
Lung function comparison between two decades in cystic fibrosis children: A single centre study
Tridello, G., Volpi, S., Assael, B. M., Meneghelli, I., Passiu, M., & Circelli, M. (2015) · Pediatric Pulmonology · doi:10.1002/ppul.23314 · Cited by 4
Richards, B., Osborne, S. R., & Simons, M. (2022) · BMC Health Services Research · doi:10.1186/s12913-021-07373-5 · Cited by 3
“Sub-optimal adherence has been linked to negative outcomes for both the individual and the health care system, including reduced baseline lung function, higher occurrence of pulmonary exacerbations, greater risk of hospitalisation, increased intravenous antibiotic usage and higher associated health care costs [7, 9].”
BackgroundMcCallion, P., Butler, J. A., Moloney, S., Bradley, J. M., & Soyza, A. D. (2022) · Journal of the Association of Chartered Physiotherapists in Respiratory Care · doi:10.56792/khov9356 · Cited by 4
Morrow, T. (2015) · PubMed · Cited by 4
Delivery of cystic fibrosis psychosocial care across developmental stages
Lynn, C., Lyons, E. R., & Muther, E. (2021) · Children s Health Care · doi:10.1080/02739615.2021.1993228 · Cited by 5
“…rates are higher than the 10% and 22% of adolescents screening positive for depression and anxiety, respectively, found in previous study examining prevalence of depression and anxiety in patients with CF (Quittner et al., 2014), perhaps pointing to the impact of COVID19 on adolescents with CF.”
BackgroundResultInfluentialWorking to Have a Normal Life With Cystic Fibrosis in an Adherence-Driven Health Care System
Macdonald, M., Lang, A., Savage, E., Chappe, V. M., Murphy, A. L., Gosse, F., & MacLean, H. J. (2019) · Respiratory Care · doi:10.4187/respcare.06493 · Cited by 6
Corten, L., & Morrow, B. M. (2019) · Physiotherapy Practice and Research · doi:10.3233/ppr-190148 · Cited by 6
Interventions for improving adherence to treatment in cystic fibrosis
Jones, S., Curley, R., Wildman, M. J., Morton, R., & Elphick, H. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011665 · Cited by 3
RetractedRozov, T., da Silva, M. T. N., Ribeiro, M. Â. G. D. O., Damaceno, N., Santana4, M. A. P. S., Maróstica, P. J. C., Melotti, R. D. C. N. C., Martins, V. D. C., Riedi, C. A., Souza, E. L., et al. (2025) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20240416 · Cited by 6
Self-citationOates, G. R., Riekert, K. A., Ford, C., Dickinson, K. M., Butcher, J. L., Naranjo, D. M., Phan, H., Daines, C. L., Grabowski, H., Schechter, M. S., et al. (2025) · Pediatric Pulmonology · doi:10.1002/ppul.71230 · Cited by 7
“Poor adherence to CF therapies has been associated with lower lung function, increased number of pulmonary exacerbations requiring intravenous antibiotics, longer hospital stays, and increased morbidity and mortality [2 – 7].”
Self-citationEhsan, Z., & Clancy, J. P. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1064308 · Cited by 2
2014 year in review: Cystic fibrosis
Savant, A. P., & McColley, S. A. (2015) · Pediatric Pulmonology · doi:10.1002/ppul.23309 · Cited by 4
“A greater complexity of the medical regimen was associated with higher adherence.(97) These findings suggest that greater severity of illness is associated with better adherence to therapies, even with increasing complexity of the regimen.”
BackgroundCounterpoint: Too little care or too little collaboration: Approaches to treatment refusal in CF
Sawicki, G. S., & Riekert, K. A. (2017) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.02.005 · Cited by 2
Self-citationTransition in Cystic Fibrosis: An International Experience
Daniel Office, & Madge, S. L. (2019) · Springer eBooks · doi:10.1007/978-3-030-23384-6_8 · Cited by 2
(2019) · Pediatric Pulmonology · doi:10.1002/ppul.22494 · Cited by 1
Quittner, A. L., & Li-Rosi, A. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816000-8.00005-0 · Cited by 2
Self-citationCultural Differences in Illness Perception and Adherence to Treatment of Cystic Fibrosis Patients
Gur, M., Yaniv, L., Teleshov, A., Bar‐Yoseph, R., Hakim, F., & Bentur, L. (2015) · Pulmonary Research and Respiratory Medicine - Open Journal · doi:10.17140/prrmoj-2-118 · Cited by 3
Understanding Treatment Adherence in Cystic Fibrosis: Challenges and Opportunities
Muther, E., Butcher, J. L., & Riekert, K. A. (2020) · Respiratory medicine · doi:10.1007/978-3-030-42382-7_22 · Cited by 4
Self-citationHoo, Z. H., & Wildman, M. J. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.09.017 · Cited by 2
Bevan, A., Hoo, Z. H., Totton, N., Girling, C., Davids, I. R., Whelan, P., Antrobus, S., Ainsworth, J., Buchan, I., Anderson, A., et al. (2022) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2022.07.011 · Cited by 2
Connett, G. J., Maguire, S., Larcombe, T., Scanlan, N., Shinde, S., Muthukumarana, T., Bevan, A., Keogh, R. H., & Legg, J. P. (2024) · medRxiv · doi:10.1101/2024.03.15.24304343 · Cited by 2
“Our results are likely to be subject to the influence of parental supervision on treatment adherence [21,22].”
Sandler, R. D., Lai, L. Y. H., Dawson, S., Cameron, S., Lynam, A., Sperrin, M., Hoo, Z. H., & Wildman, M. J. (2024) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2024.2328085 · Cited by 1
Lord, L., Langford, A. V., Wang, T., Shaw, G., Ilomäki, J., Reeve, E., & Turner, J. P. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108091 · Cited by 1
Feasibility of tracking mental health in cystic fibrosis registries: lessons from current practice
Georgiopoulos, A. M., Quittner, A. L., Schechter, M. S., He, J., Chaudhary, N., Merowitz, R. C., Wei, R., Canda, E. R., Kirby, K., Tillman, L., et al. (2026) · Respiratory Medicine · doi:10.1016/j.rmed.2026.108703 · Cited by 2
Self-citationEverhart, R. S., Ford, C., Gibson, S. L., Riekert, K. A., Duncan, C. L., Bord, E., Hoppe, J. E., Lyons, E. R., Prickett, M. H., von Isenburg, M., et al. (2026) · Annals of the American Thoracic Society · doi:10.1093/annalsats/aaoag100 · Cited by 2
Self-citationSimonetti, G., Caporale, R., Carreras, G., Lopes‐Pacheco, M., & Terlizzi, V. (2026) · Respiratory Medicine · doi:10.1016/j.rmed.2026.108853 · Cited by 1
Sandler, R. D., Lai, L. Y. H., Cameron, S., Dawson, S., Daniels, T. E., Wildman, M. J., Sperrin, M., & Hoo, Z. H. (2026) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2026.05.012 · Cited by 1
Butcher, J. L. (2021) · Respiratory medicine · doi:10.1007/978-3-030-68688-8_4 · Cited by 1
Prognosis and treatment of 46 Chinese pediatric cystic fibrosis patients
Chen, Q., Shen, Y., Xu, H., Tang, X., Yang, H., & Zhao, S. (2021) · BMC Pediatrics · doi:10.1186/s12887-021-02789-8 · Cited by 1
Mann, N., Murray, S., Hoo, Z. H., Curley, R., & Wildman, M. J. (2017) · F1000Research · doi:10.12688/f1000research.13298.1 · Cited by 1
Tappenden, P., Biz, A. N., Alava, M. H., Sasso, A., Sutton, L., Ennis, K., Elliott, R. A., & Wildman, M. J. (2023) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462322003373 · Cited by 1
“Based on medication possession ratio (MPR) data in 3,287 people with CF aged ≥6 years in the USA, adherence to preventive nebulized CF treatments has been estimated at 48 percent (6).”
BackgroundMethodMente e corpo: uma jornada interdisciplinar em Ciências da Saúde
Silva, T. K. P. (2023) · doi:10.58203/licuri.2126 · Cited by 1
Sun, H., Francis, H. M., Polo, J., Esposito, C. T., Papia, K., Yeley, J., Brant, M., Huenger, A., Wang, J., Brown, C. D., et al. (2025) · International Journal of Behavioral Medicine · doi:10.1007/s12529-025-10382-x · Cited by 3
“…medication possession ratio (cMPR), we obtained participants’ pharmacy prescription (Rx) refill histories. cMPR scores are calculated by taking the sum of the individual MPRs for each medication and dividing by the total number of medications in the regimen over a specific time period [24].”
Translational Research and Clinical Applications in the Management of Cystic Fibrosis
Quittner, A. L., Nicolais, C. J., Saez-Flores, E., & Bernstein, R. M. (2016) · Emerging issues in family and individual resilience · doi:10.1007/978-3-319-26033-4_4 · Cited by 2
Self-citationDawson, S., Cowap, L., Clark-Carter, D. D., & Girling, C. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013766 · Cited by 1
Using A Work System Framework to Investigate Pharmacists' Roles in Cystic Fibrosis Management
Abraham, O., Buechel, M., Gay, S., Szela, L., Decker, C. A., & Braun, A. T. (2022) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-27.3.270 · Cited by 2
Robinson, L., Maguire, C., Hoo, Z. H., & Wildman, M. J. (2019) · F1000Research · doi:10.12688/f1000research.21033.1 · Cited by 1
Driver, K., Major Trauma & Orthoplastics, M. R. I., Shaw-Núñez, E., & Shaffi, D. (2022) · Journal of the Association of Chartered Physiotherapists in Respiratory Care · doi:10.56792/yzdm2743 · Cited by 1
Metadata
- Authors
- Quittner, A. L., Zhang, J., Marynchenko, M., Chopra, P. A., Signorovitch, J., Yushkina, Y., & Riekert, K. A.
- Affiliations
- University of Miami (US)
- Novartis (United States) (US)
- Analysis Group (United States) (US)
- Johns Hopkins University (US)
- Corresponding author
- Quittner, Alexandra L.
- Venue
- Chest
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 146
- Issue
- 1
- Pages
- 142-151
- ISSN
- 0012-3692 (ISSN-L)
- OpenAlex
- W2070450626
- Cited by
- 250
- References
- 28
- Citations by year
- 2026: 11 · 2025: 12 · 2024: 11 · 2023: 24 · 2022: 28 · 2021: 20 · 2020: 29 · 2019: 23 · 2018: 20 · 2017: 28 · 2016: 15 · 2015: 22 · 2014: 6
- FWCI
- 24.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- CHEST Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Keywords
- cystic fibrosis, medication adherence, medication possession ratio, health care utilization, hospitalization, health care costs, outpatient visits, emergency department visits, age, privately insured patients
- MeSH terms
- Adolescent, Adult, Child, Cystic Fibrosis, Delivery of Health Care, Female, Follow-Up Studies, Humans, Immunosuppressive Agents, Male, Patient Compliance, Retrospective Studies, Health Care Costs, Disease Management, Medication Adherence, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.